ASX:PNV PolyNovo (PNV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About PolyNovo Stock (ASX:PNV) Get PolyNovo alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3.38 million shsAverage VolumeN/AMarket CapitalizationA$1.30 billionP/E Ratio247.31Dividend Yield6.86%Price TargetN/AConsensus RatingN/A Company Overview PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia. Read More Receive PNV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyNovo and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PNV Stock News HeadlinesPolyNovo Appoints Robert Douglas as Non-Executive DirectorOctober 16 at 10:50 PM | tipranks.comWhile institutions own 42% of PolyNovo Limited (ASX:PNV), individual investors are its largest shareholders with 44% ownershipOctober 16 at 9:52 PM | finance.yahoo.com$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet.October 17 at 2:00 AM | Weiss Ratings (Ad)PolyNovo Appoints Bruce Peatey as CEO to Drive Global ExpansionOctober 16 at 11:50 AM | msn.comPolyNovo Appoints Robert Douglas as Non-Executive DirectorOctober 13, 2025 | tipranks.comStock Tips: You might not want to sleep on this week’s picksOctober 4, 2025 | msn.comAnother Aussie biotech says 100% US pharmaceutical tariffs won't affect itSeptember 29, 2025 | msn.comPolyNovo Director Increases Stake with Share AcquisitionSeptember 17, 2025 | tipranks.comSee More Headlines PNV Stock Analysis - Frequently Asked Questions What other stocks do shareholders of PolyNovo own? Based on aggregate information from My MarketBeat watchlists, some other companies that PolyNovo investors own include Align Technology (ALGN), Amgen (AMGN), Docusign (DOCU), Panoramic Resources (PAN), Plug Power (PLUG) and Roku (ROKU). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:PNV CIKN/A Webwww.polynovo.com.au Phone61 3 8681 4050FaxN/AEmployees237Year FoundedN/AProfitability EPS (Trailing Twelve Months)A$0.01 Trailing P/E Ratio247.31 Forward P/E RatioN/A P/E Growth2.63Net IncomeA$5.26 million Net Margins5.10% Pretax MarginN/A Return on Equity7.45% Return on Assets0.56% Debt Debt-to-Equity Ratio21.32 Current Ratio3.41 Quick Ratio1.58 Sales & Book Value Annual SalesA$103.23 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow207.50 Book ValueA$0.10 per share Price / BookN/AMiscellaneous Outstanding Shares690,760,000Free FloatN/AMarket CapA$1.30 billion OptionableNot Optionable Beta1.67 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (ASX:PNV) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyNovo Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyNovo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
